Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620674 | 0.90 | KCNH2 (0.40) | MCHR1KCNH2KCNQ1CACNA1CHTR7 | |
| SCHEMBL619920 | 0.89 | KDM4E (0.39) | MCHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL620152 | 0.88 | HPGD (0.46) | MCHR1ALDH1A1HPGDPOLBHPGDS | |
| SCHEMBL622377 | 0.85 | HPGDS (0.40) | KCNH2KCNQ1CACNA1CHTR7HPGDS | |
| SCHEMBL619473 | 0.85 | MCHR1 (0.40) | MCHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL621527 | 0.82 | HTR7 (0.45) | MCHR1KCNH2HTR7POLBHPGDS | |
| Hydrochloric Acid SCHEMBL6079190 | 0.82 | SLC2A1 (0.51) | KCNH2 | |
| SCHEMBL621308 | 0.78 | KCNH2 (0.39) | MCHR1KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL5309916 | 0.78 | SLC2A1 (0.61) | KCNH2 | |
| SCHEMBL6079601 | 0.76 | KCNH2 (0.57) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | BASILEA PHARMACEUTICA AG | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040957-A1 | Novel Bicyclic Antibiotics | C5, C1S, CBR3 | MCHR1 533/4885KDM4E 3573/4885ALDH1A1 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.